Clinical Trials List
2022-05-01 - 2025-05-09
Phase III
Terminated5
ICD-10C56.1
Malignant neoplasm of right ovary
ICD-10C56.2
Malignant neoplasm of left ovary
ICD-10C56.9
Malignant neoplasm of unspecified ovary
ICD-10Z51.12
Encounter for antineoplastic immunotherapy
ICD-9183.0
Malignant neoplasm of ovary
-
-
Trial Applicant
MEDPACE TAIWAN LIMITED
-
Sponsor
-
-
Trial scale
Multi-Regional Multi-Center
-
Update
2026/05/14
Investigators and Locations
Co-Principal Investigator
- Huann-Cheng Horng Division of Obstetrics & Gynecology
- Yi-Jen Chen Division of Obstetrics & Gynecology
- 沈書慧 Division of Obstetrics & Gynecology
The Actual Total Number of Participants Enrolled
0 Terminated
The Actual Total Number of Participants Enrolled
0 Terminated
Co-Principal Investigator
- Meng-Ru Shen Division of Obstetrics & Gynecology
- 黃蘭茵 Division of Obstetrics & Gynecology
- 林語涵 Division of Obstetrics & Gynecology
- Cheng-Yang Chou Division of Obstetrics & Gynecology
- 江佳蓉 Division of Obstetrics & Gynecology
- 鄭雅敏 Division of Obstetrics & Gynecology
The Actual Total Number of Participants Enrolled
0 Terminated
The Actual Total Number of Participants Enrolled
0 Terminated
The Actual Total Number of Participants Enrolled
0 Terminated
Study Contacts
- -
Condition/Disease
Objectives
Test Drug
Active Ingredient
Dosage Form
Dosage
Endpoints
Inclution Criteria
Exclusion Criteria
The Estimated Number of Participants
-
Taiwan
35 participants
-
Global
376 participants
